417 / 1631
Patients with drug-related AEs (≥10%), serious AEs (≥1%), or AEs
leading to discontinuation (≥1%)
Overall population
n = 243
Drug-related AEs, %
Any grade
Grade 3–4
Fatigue
23
1
Diarrhea
15
1
Infusion-related reaction
14
<1
Rash
12
1
Drug-related serious AEs, %
Infusion-related reaction
2
<1
Pneumonitis
1
0
Drug-related AEs leading to discontinuation, %
Pneumonitis
2
0
Autoimmune hepatitis
1
1
Engert et al, EHA 2017
Phase 2 CheckMate 205
Safety Outcomes after Extended Follow-up